QDTI

Exciting news! QDTI will be at the AD/PD - Advances in Science & Therapy's AD/PD 2023 event in Gothenburg from March 28 - April 1, discussing ultrasensitive biomarker detection and its impact on Alzheimer's and Parkinson's research. Join us in shaping the future of brain health!

Colin Connolly, Director of Technology at QDTI, describes the nuts and bolts of the QDTI platform at the National Institutes of Health (NIH) Virtual Workshop: Near-term Applications of Quantum Sensing Technologies in Biomedical Sciences.

Join Colin Connolly, Director of Technology at QDTI, to discuss opportunities and challenges of quantum-sensing in clinical applications and life sciences research.

This discussion will take place on January 5, 2023, at 12:25 PM EST, at the National Institutes of Health (NIH) Virtual Workshop: Near-term Applications of Quantum Sensing Technologies in Biomedical Sciences.

Catch up as well on this event with our co-founders Ronald Walsworth and Mikhail Lukin.

https://datascience.nih.gov/news/nih-virtual-workshop-near-term-applications-of-quantum-sensing-technologies-in-biomedical-sciences

John Pena, our CEO, along with Nicolas Gisin, Grégoire Ribordy, Patrick Maletinsky, Nate Gemelke, Christopher Monroe, and others, are discussing the application of quantum technologies and what it means to be a startup at the Constructor Group Insights in Technology conference 2022: Geneva Edition.

John Pena, at the Constructor Group Insights in Technology Conference 2022 event, highlights how QDTI quantum-powered biomarker detection platform can boost research and diagnostics.

At the Quantum Business Network QBN sensing event, Matthew Markham illustrates using Element Six NV center diamonds with the QDTI use-case.

QDTI assays are easier to run, eliminating error-prone and time-intense complexity. New research illustrates QDTI's ease of use.

Follow the link to the full paper: https://qdti.com/mgh-research-s.

"QDTI assay had a significantly shorter turnaround time and reduced sample preparation effort." demonstrates the new study performed at Massachusetts General Hospital.

Get the details at https://qdti.com/mgh-research-s.

A new independent publication comparing QDTI and Luminex performed at Massachusetts General Hospital describes QDTI's ultrasensitivity, superior speed, ease of use, and cost-efficiency. To find out more, visit https://qdti.com/mgh-research-s.

Identify fluid of response and clinical efficacy for with technology. https://qdti.com

Fluid can aid understanding of biological mechanisms and therapeutic efficacy in mental health conditions. technology provides a platform for further investigation and research. https://qdti.com

FIFA is evaluating the benefits of additional permanent substitutions for cases of an actual or suspected concussion.
Concussions in professional sports can lead to short- and long-term negative effects on athletes. If mistreated or undiagnosed, concussions can even lead to neurodegenerative diseases.

In 2021 FIFA trialed additional permanent substitutions to withdraw players in order to prevent multiple head injuries, and reduce the pressure on medical personnel to make a quick assessment.

At QDTI, we work with organizations to bring rapid and accurate blood-based tests that could indicate if an individual has experienced a concussion in order to receive timely and effective treatment. Moreover, a straightforward, very simple, sample preparation protocol could make QDTI a perfect solution for rapid, in-field use.
Visit this link for more details on the FIFA trial:
https://www.fifa.com/tournaments/mens/clubworldcup/qatar2020/news/fifa-to-trial-concussion-substitutes-at-fifa-club-world-cuptm

Our co-founder, Mikhail Lukin, and a team of researchers document the presence of quantum spin liquids, a never-before-seen state of matter.
In 1973, physicist Philip W. Anderson theorized the existence of a new state of matter — the quantum spin liquids. In this state, unlike in solid-state magnets, the electrons don’t stabilize when cooled, don’t form into a solid, and are constantly changing and fluctuating (like a liquid) in one of the most entangled quantum states ever conceived. The unique properties of quantum spin liquids allow for promising applications in high-temperature superconductors and quantum computers. But until now, no one had ever actually seen or verified the existence of this state of matter.
And now, a team of Harvard-led physicists, including Mikhail Lukin, have finally documented this long-sought-after, exotic state of matter.
For more entangled details on quantum spin liquids, check out this article: https://news.harvard.edu/gazette/story/2021/12/harvard-led-team-takes-step-in-quest-for-quantum-computing/

Rapid and straightforward exosome detection, and the biomarkers they contain, hold great potential as a tool for non-invasive cancer detection and monitoring. Yet up until now, the process remained challenging.

A new report describes a simple method for exosome surface protein detection. It uses quantum dots coupled with immunomagnetic capture and enrichment. This approach is less than five hours long and only requires microliters of diluted plasma without pre-purification. This makes it practical for routine use for basic vesicle research and clinical applications like non-invasive cancer detection and monitoring.

Here at QDTI, we are working to enable exosome detection in order to exploit the platform's less than 1-hour of hands-on time and need for less than 5µL sample volume.

Visit this link to know more:
https://pubmed.ncbi.nlm.nih.gov/34361239/

We are happy, EETimes featured QDTI as an example of how diamond quantum technology is applied to tackle medical challenges:
https://www.eetimes.com/diamond-quantum-technology-for-medical-imaging/

280 million people in the world are suffering from depression. Researchers from the University of Illinois Chicago found a biomarker for diagnosing depression and determining drug response.
The new study has identified the cellular biomarker for translocation of Gs alpha from lipid rafts. The biomarker can be identified through a blood test. The test can indicate the presence of depression and show a therapeutic response with a single biomarker.
To know more, visit: https://www.technologynetworks.com/neuroscience/news/a-biomarker-for-diagnosing-depression-and-determining-drug-response-357146

QDTI is eco-friendly on top of being rapid and ultrasensitive. And we are proud to be a part of Greentown Labs.
By now, you already know that QDTI's quantum-based platform enables rapid and ultrasensitive detection of biomarkers in small sample volumes of whole blood, serum, CSF, and others. One of the reasons for this is that QDTI eliminated most washing steps.
But there is another excellent benefit of fewer washing steps. The QDTI platform uses at least 90% fewer solvents and plastic consumables. Moreover, QDTI decreases hands-on time and power consumption associated with it.
Therefore, QDTI renders an eco-friendlier platform by generating 90%+ less biohazardous waste from testing and consuming less power than conventional approaches. This highlights our core value and commitment to a clean and sustainable future.
Therefore, we are proud to be a part of , the largest climate tech startup incubator in North America, home to more than 180 startups that are building a sustainable future for all.
Let's build eco-friendly testing together!
Visit this link for more:
https://greentownlabs.com/greentown10/

Ovarian cancer afflicts more than 300,000 women each year worldwide. At the latest stage, only 20% of women have chances for long-term survival. But early detection could reduce mortality by 10–30%.
There are two critical factors for efficient early detection. The first one is the frequency of testing. Screening every three months proved more effective than an annual one, requiring the procedure to be fast and affordable. The second factor is the use of novel biomarker panels. For instance, alterations in blood ctDNA can complement CA125 in effectively detecting early-stage disease.
QDTI's biomarker detection platform tackles both factors. QDTI drastically reduces the cost of biomarker detection by decreasing hands-on time and consumable consumption by up to 90%. Moreover, QDTI can enable one device for both protein and soon nucleic acid detection.

To know more, visit the link below:
https://www.nature.com/articles/s43856-021-00037-9

We congratulate our co-founder Ronald Walsworth on winning the 2020 Best Paper Award at the International Symposium for Testing and Failure Analysis (ISTFA) Workshop for the paper titled “Backside Integrated Circuit Magnetic Field Imaging with a Quantum Diamond Microscope.”

The paper describes a new backside IC magnetic field imaging method using QDM nitrogen-vacancy magnetometry.

To know more, visit the link below:
https://ece.umd.edu/news/story/qtcmitre-collaboration-receives-best-paper-award-at-edfas-2020

Together with Element Six, we released a white paper highlighting how a quantum sensing technology can enable rapid, easy-to-use, and ultrasensitive biomarker detection.

QDTI combines a unique imaging solution with a novel magnetic-based assay technology to provide breakthrough biomarker detection. A diamond nitrogen vacancy sensor powers the imaging solution. Initially theoreticized in the 2000s, these sensors can image magnetic fields down to the millimeter-scale with the sub-micrometer resolution, collecting data in seconds.

The target biomarker in a sample can be specifically labeled with a magnetic tag and then placed on the imaging platform for analysis. The quantum sensor is then able to measure directly the labeled biomarkers, thereby providing a digital measurement of the desired events.

The use of quantum diamonds sensors and magnetic tags provides advantages over fluorescent or colorimetric approaches in terms of speed, ease of use, and sensitivity.

To find out more, check out our white paper: https://onlinelibrary.wiley.com/doi/10.1002/phvs.202270107

Before rheumatoid arthritis (RA) symptom manifestation, IL-6 contributes to the differentiation of B cells into autoantibody-producing plasma cells. These autoantibodies have been found in RA patients 10+ years before diagnosis.

Serum levels of IL-6 are up to about 10 times higher in patients with RA than in healthy controls. Moreover, IL-6 levels in the joint fluid of patients with RA are 100- to 1000-fold more elevated than in patients without RA.

In the recent podcast at raandil6.com, Dr Gordon Lam discuss the critical role of IL-6 between innate and adaptive immune responses in RA.

QDTI's instrument can detect IL-6 levels in different fluids with ultra sensitive precision and, hence, assist in predicting RA.

To know more, visit:
https://www.raandil6.com/il6-in-ra

Do you know that about one million Americans annually continue to experience symptoms three months after a concussion? Adolescents are at a higher risk of delayed recovery. It is known as persistent post-concussion syndrome.

In upcoming research, Keck School of Medicine of USC will evaluate children with a concussion to identify a set of biomarkers predictive of persistent post-concussion symptoms.

Here at QDTI, we are using quantum technology to identify biomarkers that could help assess the lingering presence of a concussion.

To learn more about Keck School of Medicine's research, check the link below:

https://keck.usc.edu/national-institutes-of-health-awards-10-million-for-pediatric-concussion-research/

BestStartup.us recognized Quantum Diamond Technologies Inc (QDTI) as a top pick for the best Massachusetts based Image Recognition companies!

The full article is here: https://lnkd.in/eVUJMg_h

Dr. Peter Schueler explores how fluid biomarkers can drastically change our approaches to neurodegenerative diseases. Biomarkers can hint at these diseases 20 years before clinical symptoms. Yet, currently used imaging biomarkers are expensive and hard to access. Fluid biomarkers, even still in development, on the other hand, lack these issues.
QDTI provides the solution that perfectly fits this task! QDTI is ultrasensitive, detects target proteins in whole blood, and requires as little as five microlitres of a sample. All important for neurological samples.
For more on Dr Peter Schueler's article: https://hubs.ly/H0-yhhS0

Ronald Walsworth, a QDTI co-founder and scientific advisor, talked about how diamond defects can be used as exceptional magnetic field sensors in the recent episode of the Joint Quantum Institute podcast.

Want to know how QDTI uniquely applies this approach for ultrasensitive biomarker detection? Check this link out:
https://hubs.ly/H0-cM0w0

Copy this link to listen to The Joint Quantum Institute Podcast: https://hubs.ly/H0-cPwV0

We congratulate Mikhail Lukin, our scientific adviser and co-founder, on receiving the Norman F. Ramsey Prize in Atomic, Molecular and Optical physics, and in Precision Tests of Fundamental Laws and symmetries. His contributions to quantum information science, sensing including the development of Rydberg atom-based quantum simulators have received special attention from the world of physics.

Ahh, pipettors. Every day we all spend long hours using them. Thanks to QDTI quantum imaging capability - our assay involves 90% less hands-on time than existing technologies. So, you could spend more time on your breakthrough research and less working with pipettors.

Removing the need for repeated washing of samples, there is minimal material loss. The QDTI diagnostic protocol requires only a few microliters (vs. 10s, 100s or more!) of sample to perform the assay – a critical benefit when sample availability is limited.